บทบาทของพยาบาลในการดูแลผู้ป่วยที่ได้รับยายับยั้งการทำงานที่อิมมูนเช็กพอยต์

Akradach Bamrungnam

Authors

Akradach Bamrungnam Medical Oncology Unit, Department of Nursing, King Chulalongkorn Memorial Hospital

Keywords:

role of nurses, immunotherapy, immune checkpoint inhibitors

Abstract

Immune checkpoint inhibitors or immunotherapy have been increasingly used in cancer treatment. If patients do not receive appropriate care before, during, and after receiving immunotherapy, it may affect the efficacy and safety of the treatment. Therefore, nurses responsible for drug administration must have appropriate knowledge and competence by applying knowledge gained from empirical evidence to patient care. This article discusses the mechanism of action, drug types, and the role of nurses in the process before, during, and after receiving immunotherapy.

References

Immune Checkpoint Inhibitors - NCI [Internet]. [cited 2024 Aug 25]. Available from: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors

Wiley K, Lefebvre KB, Wall L, Baldwin-Medsker A, Nguyen K, Marsh L, et al. Immunotherapy Administration: Oncology Nursing Society Recommendations. Number 2 /April 2017 [Internet]. 2017 Apr 1 [cited 2024 Aug 26];21:5–7. Available from: https://www.ons.org/cjon/21/2-0/supplement/immunotherapy-administration-oncology-nursing-society-recommendations

Immunotherapy Is Rapidly Changing Nursing Practice [Internet]. [cited 2024 Aug 26]. Available from: https://www.oncnursingnews.com/view/immunotherapy-is-rapidly-changing-nursing-practice

Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology [Internet]. 2022 May 1 [cited 2024 Aug 25];29:3044. Available from: /pmc/articles/PMC9139602/

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. New England Journal of Medicine [Internet]. 2018 Jan 11 [cited 2024 Aug 25];378:158–68. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra1703481

Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer [Internet]. 2017 Nov 21 [cited 2024 Aug 25];5:1–28. Available from: https://link.springer.com/articles/10.1186/s40425-017-0300-z

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology [Internet]. 2021 Dec 20 [cited 2024 Aug 25];39:4073–126. Available from: https://ascopubs.org/doi/10.1200/JCO.21.01440

3549-Immunotherapy blood test monitoring recommendations | eviQ [Internet]. [cited 2024 Aug 25]. Available from: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/immunological/3549-immunotherapy-blood-test-monitoring-recommend#history

Peterson, DNP, RN, AGNP-c C. An AP Perspective on Infusion Reactions in the Era of Immunotherapy. J Adv Pract Oncol [Internet]. 2022 Apr 1 [cited 2024 Aug 25];13:247. Available from: /pmc/articles/PMC9126347/

Peterson C. Management of Immunotherapy Infusion Reactions. 2023.

Barroso A, Estevinho F, Hespanhol V, Teixeira E, Ramalho-Carvalho J, Araújo A. Management of infusion-related reactions in cancer therapy: strategies and challenges. ESMO Open. 2024;9:102922.

Siegel RD, LeFebvre KB, Temin S, Evers A, Barbarotta L, Bowman RM, et al. Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards. https://doi.org/101200/OP2400216 [Internet]. 2024 May 22 [cited 2024 Aug 25]; Available from: https://ascopubs.org/doi/10.1200/OP.24.00216

Preparation, Storage and Administration of KEYTRUDA® (pembrolizumab) | HCP [Internet]. [cited 2024 Aug 25]. Available from: https://www.keytrudahcp.com/dosing/preparation-storage-administration/

LIBTAYO® (cemiplimab-rwlc) Dosing & Administration [Internet]. [cited 2024 Aug 25]. Available from: https://www.libtayohcp.com/dosing

IMFINZI® (durvalumab) Dosing for Unresectable Stage III NSCLC [Internet]. [cited 2024 Aug 25]. Available from: https://www.imfinzihcp.com/non-small-cell-lung-cancer/stage-3/durvalumab-nsclc-infusion-dosage.html

Saad P, Kasi A. Ipilimumab. StatPearls [Internet]. 2023 Apr 10 [cited 2024 Aug 25]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK557795/

Preparation & Administration | OPDIVO® (nivolumab) [Internet]. [cited 2024 Aug 25]. Available from: https://www.opdivohcp.com/dosing/preparation-administration

TECENTRIQ® (atezolizumab) offers 3 flexible dosing options [Internet]. [cited 2024 Aug 25]. Available from: https://www.tecentriq-hcp.com/sclc/dosing-and-administration/dosing.html

Dosing & Administration | BAVENCIO® (avelumab) For HCPs [Internet]. [cited 2024 Aug 25]. Available from: https://www.bavencio.com/en_US/hcp/uc-home/dosing.html

Sujira Foongfaung. Nursing Management of Hypersensitivity and Infusion Reaction from Intravenously Administered Chemotherapeutic Agents. Thai Cancer J. 2018;38:20-41.

Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer. Asia Pac J Oncol Nurs [Internet]. 2017 Apr [cited 2024 Aug 24];4:127–35. Available from: https://pubmed.ncbi.nlm.nih.gov/28503645/

Nguyen EE, Winokur E. Immunotherapy Adverse Events: An Emergency Nursing Perspective. J Emerg Nurs [Internet]. 2019 Nov 1 [cited 2024 Aug 24];45:699–706. Available from: https://pubmed.ncbi.nlm.nih.gov/31402127/

Rubin KM, Hoffner B, Bullock AC. Caring for Patients Treated with Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. Semin Oncol Nurs [Internet]. 2019 Oct 1 [cited 2024 Aug 24];35. Available from: https://pubmed.ncbi.nlm.nih.gov/31514991/

Teixeira-Poit SM, Sawicki K, O’Kelley W, Hardin M, Jenkins M, Gudena V. Efficacy of a Patient Education Session for Cancer Patients Receiving Immunotherapy. Semin Oncol Nurs [Internet]. 2023 Aug 1 [cited 2024 Aug 24];39. Available from: https://pubmed.ncbi.nlm.nih.gov/37179177/